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Abstract
Background: Spinal fractures are a common source of morbidity in cancer patients. Balloon
Kyphoplasty (BKP) is a minimally invasive procedure designed to stabilize fractures and correct
vertebral deformities. We performed a meta-analysis to determine the efficacy and safety of BKP
for spinal fractures in cancer patients.
Methods: We searched several electronic databases up to September 2008 and the reference lists
of relevant publications for studies reporting on BKP in patients with spinal fractures secondary to
osteolytic metastasis and multiple myeloma. Outcomes sought included pain relief, functional
capacity, quality of life, vertebral height, kyphotic angle and adverse events. Studies were assessed
for methodological bias, and estimates of effect were calculated using a random-effects model.
Potential reasons for heterogeneity were explored.
Results: The literature search revealed seven relevant studies published from 2003 to 2008, none
of which were randomized trials. Analysis of those studies indicated that BKP resulted in less pain
and better functional outcomes, and that these effects were maintained up to 2 years post-
procedure. While BKP also improved early vertebral height loss and spinal deformity, these effects
were not long-term. No serious procedure-related complications were described. Clinically
asymptomatic cement leakage occurred in 6% of all treated levels, and new vertebral fractures in
10% of patients. While there is a lack of studies comparing BKP to other interventions, some data
suggested that BKP provided similar pain relief as vertebroplasty and a lower cement leakage rate.
Conclusion: It appears that there is level III evidence showing BKP is a well-tolerated, relatively
safe and effective technique that provides early pain relief and improved functional outcomes in
patients with painful neoplastic spinal fractures. BKP also provided long-term benefits in terms of
pain and disability. However, the methodological quality of the original studies prevents definitive
conclusions being drawn. Further investigation into the use of BKP for spinal fractures in cancer
patients is warranted.
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Background
Spinal fractures are a common source of morbidity in
patients with osteolytic metastasis and multiple myeloma
[1-3]. Located principally in the thoracic and lumbar
spine [4,5], these fractures often result in intractable back
pain and impaired mobility because of vertebral height
loss and spinal deformity [2,3,6]. In addition, the severe
physiological and functional consequences have negative
impacts on physical function, pulmonary capacity, nutri-
tional state, psychological well-being and quality of life.
Furthermore, spinal fractures increase the risk of new frac-
tures, the number of hospitalizations and the incidence of
all-cause mortality [1,3,6-8].
Traditional medical and surgical options often prove
inadequate in spinal fracture patients. Due to the fragility
and comorbidities associated with these patients, the sur-
gical risk is high and open surgery is reserved only for
cases with neurological involvement [1,5,6]. Additionally,
non-surgical supportive treatments (e.g., analgesics, bed
rest, use of braces or other external support systems, radi-
otherapy, hormone therapy, chemotherapy, radiophar-
maceuticals and bisphosphonates) show variable
outcomes, and single modality approaches are rarely
effective [1,6,9,10].
In recent years, minimally invasive surgical techniques
have emerged as an attractive option that reduce recovery
time and surgical risks [1,5,11,12]. Balloon Kyphoplasty
(BKP) is a percutaneous procedure used to relieve pain,
restore vertebral height and reduce biomechanical altera-
tions of the spine caused by fractures, and in turn improve
physiological and functional outcomes [12-14]. BKP
involves the introduction of a cannula into the vertebral
body under image guidance, followed by the insertion of
an inflatable bone tamp which is used to elevate the end-
plates. This reduces the deformity and creates a cavity
within the vertebral body, and this cavity is subsequently
filled with bone cement (polymethyl methacrylate,
PMMA) in a controlled manner so as to minimize the risk
of cement leakage [12-14].
Several reviews have recently shown that BKP is a rela-
tively effective and safe treatment for painful osteoporotic
vertebral fractures, its most common indication
[12,15,16]. However, to our knowledge, BKP use in cancer
patients has not been specifically analyzed.
The present study performed a meta-analysis of published
reports describing the use of BKP in patients with spinal
fractures of malignant origin. The study examined patient
outcome data in order to determine the efficacy and safety
of using BKP for spinal fractures in cancer patients.
Methods
A systematic literature search was carried out up to Sep-
tember 2008 using several databases (MEDLINE,
EMBASE, CINAHL, ISI Proceedings, The Cochrane
Library, DARE, NHS EED and the HTA Database of the
CRD). The search strategy was: #1: (balloon kyphoplasty),
#2: (fracture*) or (vertebra*) or (neoplasm*) or
(tumor*), #3: #1 and #2. There were no language restric-
tions. The search was completed manually using refer-
ences from identified studies and reviews [17], and
contact was made with experts in the field. No contact was
made with industry.
Inclusion criteria
Sackett's criteria [18], duly amended, were applied as fol-
lows: 1) population: studies conducted on more than 10
adults with spinal fractures of malignant origin; 2) inter-
vention: BKP; 3) comparator: any medical or surgical
treatment; 4) results: including a description of clinical
outcomes regarding at least one of the following variables:
pain, functional capacity, quality of life, vertebral height,
kyphotic angle, cement leakages, clinical complications
and new vertebral fractures.
No limitations were placed on study design or duration of
follow-up [17].
Selection of studies
The located studies were examined by two independent
reviewers, and any disagreements were settled by discus-
sion of the respective study data. During the data screen-
ing and extraction process, reviewers were not blinded to
authors, institutions, or journals.
Data extraction
Original data were extracted on a standard form that
included details of the study design, information on the
study population, and information on efficacy and safety
outcomes.
Analysis of methodological quality and scientific evidence
This was conducted in accordance with validated recom-
mendations [19]. The possibility of bias in the studies was
evaluated using published guidelines for systematic
reviews [20].
Data analysis and synthesis of results
To obtain an overall measure of the efficacy and safety of
BKP, standard meta-analytical techniques were applied
using the SE-STATA 9 computer software package (Stata-
Corp LP Texas USA 1984-2007). Meta-analysis was con-
ducted using a random-effects model [21]. Dichotomous
outcomes were analyzed using rate ratios (RR) and corre-
sponding 95% confidence interval. Continuous variablesBMC Palliative Care 2009, 8:12 http://www.biomedcentral.com/1472-684X/8/12
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were analyzed using standardized or weighted differences
in means (with 95% confidence intervals) between pre-
and post- treatment values at the respective assessment
dates. When an original study failed to provide a standard
deviation of a continuous variable, it was estimated from
the publication data (range or P-value) [22]. When the
original study provided a standard error rather than a
standard deviation, the latter was calculated using stand-
ard formulas. The degree of inconsistency across studies
was evaluated using I2 statistics, considering a value > 50%
to be relevant [20]. We used sensitivity analysis to explore
statistical heterogeneity. Results were deemed significant
at a P-value < 0.05. In accordance with recent publica-
tions, funnel-plots were not used to estimate possible
publication bias [23].
Results
The literature selection process is summarized in Figure 1.
After excluding references without an abstract and redun-
dancies arising from the use of several databases, 208
potentially relevant references were identified. Eleven of
these publications [24-34] were selected based on our
inclusion criteria. Of those, 4 were excluded [24,29,31,32]
because of data duplication in subsequent or more com-
plete publications [25,33,34]. Hand searching of retrieved
articles yielded no additional studies to be included.
The seven remaining studies were the basis of the present
meta-analysis. These studies comprised three retrospective
[26,28,30] and four prospective [25,27,33,34] single-
center clinical series published from 2003 to 2008, and
included data on 306 patients with 741 treated levels. The
principal characteristics and quality assessment of these
studies are summarized in Tables 1 and 2. The patients
had a mean age of 62 years, 51% were male and 57% had
multiple myeloma. The population mostly comprised
patients with persistent pain secondary to thoracic or lum-
bar collapses, despite painkillers and medical therapy
[25,27,30,34]. Around 30% of patients required devices
to assist with walking. In all studies, symptomatic levels
were identified by correlating the clinical data with MRI
findings of marrow signal changes. In all but Kose's study
[30], BKP was performed under general anesthesia. The
mean number of spinal levels treated varied among the
studies (range:1-6). Follow-up periods varied from 3
months [27] to 2 years [33,34].
The studies were examined for bias in accordance with
validated references [19,20]. We found that most studies
were designed to avoid most types of bias, with some
exceptions (Table 2). However, a number of studies did
not provide information on whether the results were
assessed independently (Table 2). No study was rand-
omized and the level of evidence corresponded to grade
III [19]. However, the samples were representative and the
studies were found to provide effective information on
pre- and post-intervention variables and evaluated objec-
tive outcomes, and more than half reported follow-up of
over 80% of patients [20].
Efficacy outcomes
Pain Relief
The six studies that analyzed this variable before and after
BKP reported reductions in pain intensity, and that the
reduction was maintained during follow-up [see Addi-
tional file 1]. Combined analysis of studies that contrib-
uted Visual Analog Scale (VAS) data showed that BKP
resulted in a reduction in mean pain score both in the
postoperative period and at the end of the follow-up
period (Table 3). A substantial level of inconsistency was
found across studies, with the mean pre-procedure VAS
being related to the effect size.
Fourney's study [26] showed that both BKP and vertebro-
plasty relieved pain to a similar degree in a high percent-
age of patients. Kose's study [30] indicated that although
both BKP and vertebroplasty relieved pain, BKP provided
greater pain relief at 6 and 12 months postoperatively [see
Additional file 1].
Functional Capacity
Changes in functional capacity were recorded in four stud-
ies using the validated Oswestry Disability Index (ODI 0-
100) [25,27,33,34]. In all studies, comparisons between
preoperative and postoperative values showed a signifi-
cant decrease in ODI scores after treatment, indicating a
decrease in impairment [see Additional file 1]. The com-
bined analysis indicated improved functional capacity
after BKP, and that the improvement was sustained over
the follow-up period (Table 3). Heterogeneity was found
to be related to differences in the mean basal pre-proce-
dure ODI scores.
Study selection and inclusion process Figure 1
Study selection and inclusion process.BMC Palliative Care 2009, 8:12 http://www.biomedcentral.com/1472-684X/8/12
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Individual studies [26,28,30] reported that most patients
were mobilized on the same day following the procedure
and regained activity, social functions and physical capac-
ity.
Quality of Life
All studies reported obvious improvement in patient
quality of life after the procedure. However, only one
study [25] evaluated the effect on quality of life using the
SF-36 questionnaire. That study found significant
improvements in physical function, physical role, bodily
pain, vitality, social functioning, and mental health, but
no improvements in general health perception or emo-
tional role [see Additional file 1].
Kyphotic Deformity
Three studies analyzed this variable using the absolute
Cobb angle value [26,32,33]. Joint analysis in these stud-
ies found that BKP resulted in a decrease in the angle's
absolute value (Table 3), although with a high degree of
heterogeneity and a wide variation among studies in both
baseline and post-treatment values of deformity [see
Additional file 1]. Follow-up analysis showed partial loss
of the initial effect, with the absolute value of the angle
ultimately decreasing to preoperative levels (Table 2) and
the pooled differences being not significant (Table 3).
Vertebral Height
Although the number of levels varied among studies, each
study in which this variable was recorded [25-
27,30,33,34] reported a post-BKP increase in vertebral
height. However, the increase was expressed differently in
each study [see Additional file 1]. Several authors [25-27]
recorded the percentage of vertebral height restoration
after BKP, and the mean restoration across these studies
was 47% (Table 3). In contrast, Pflugmacher [33,34]
Table 1: Principal characteristics of the included studies
Author/year/
country
Design No. of patients/
levels
Inclusion criteria Exclusion criteria Estimated age of VF Follow-up
Lieberman [25]
2003. USA
P 63/264 Painful progressive 
osteolytic VF secondary to 
multiple myeloma
Unstable (by virtue of 
myelomatous destruction of 
the posterior elements) or 
with retropulsed tissue or 
bone fragments.
11 mo
(0.5-24 mo)
4 mo
Fourney [26]
2003. USA
R BKP:15/32
VP: 34/65
VF with disabling pain 
refractory to prior medical 
and/or physical therapy in 
cancer patients
Epidural compression of the 
neural elements; failure to 
localize symptomatic levels; 
radicular pain; intolerance 
to being positioned prone 
or significant medical 
contraindications
3.2 mo
(1 wk-26 mo)
4.5 mo
Lane [27]
2004. USA
P 19/46 Painful VF secondary to 
multiple myeloma
Not reported >3 mo 3 mo
Vrionis [28]
2005. USA
R 50/128 VF with intractable 
mechanical pain refractory 
to medical and/or physical 
therapy in cancer patients.
Overt instability; clinical 
and/or radiological spinal 
cord compression; lesions 
above T3; absence of 
correlating symptoms (not 
mechanical pain and/or not 
localized to the area of VF).
13 cases:3 mo
35 cases: 10 mo
9 mo
Kose [30]
2006. Turkey
R BKP: 18/22
VP: 16/26
Symptomatic VF in 
myeloma with pain 
refractory to medical 
therapy.
Canal stenosis Not reported 12 mo
Pflugmacher[33]
2007. Germany
P 26/59 VF with severe refractory 
pain in patients with 
myeloma
Not reported Not reported 24 mo
Pflugmacher[34]
2008. Germany
P 65/99 Metastatic VF with severe 
and refractory back pain.
Not reported Not reported 24 mo
P: Prospective, R: Retrospective, BKP: Balloon Kyphoplasty, VP: Vertebroplasty, VF: Vertebral FractureBMC Palliative Care 2009, 8:12 http://www.biomedcentral.com/1472-684X/8/12
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Table 2: Quality assessment of included studies
Selection Bias Procedure Bias Detection Bias Attrition Bias
Author/year Representative 
sample
Consecutive 
cases
Specific Co-
intervention
Pre-post 
assessment
Independent/
blind 
assessment
Objective 
Results
Follow-up 
>80%
Lieberman[25]
2003.
Yes Yes No Yes Yes Yes NR
Fourney[26]
2003.
Yes Yes Yes Yes Yes Yes No
Lane[27]
2004.
Yes Yes Yes Yes NR Yes Yes
Vrionis[28]
2005.
Yes Yes Yes Yes NR NR Yes
Kose[30]
2006.
Yes NR Yes Yes NR Yes Yes
Pflugmacher[33]
2007.
Yes NR Yes Yes NR Yes Yes
Pflugmacher[34]
2008.
Yes Yes Yes Yes Yes Yes No
NR: Not reported
Table 3: Efficacy of BKP for malignant spinal fractures: Results of meta-analysis
Variable Studies providing data N° patients/levels Size of effect (95%CI); P-value; I2
Pain: VAS score (0-10)
Basal-postoperative 4 [25,30,33,34] 172 patients SMD: 3.85 (2.99, 4.71); p < .001; 79%
Baseline-end of follow-up 3 [30,33,34] 109 patients SMD: 4.27 (2.38, 6.21); p < .001; 93%
Functional capacity:
ODI (0-100)
Baseline-postoperative 4 [25,27,33,34] 173 patients WMD:-28.78 (-11.5,- 46.0);p = .001; 99%
Baseline-<6 months 2 [25,27] 82 patients WMD:-16.39 (-14.25,-18.5);p = .001; 0%
Baseline-2 years 2 [33,34] 91 patients WMD:-41.95 (-39.42, -44.5);p = .001; 0%
Kyphotic deformity (Cobb angle):
Basal-postoperative 3 [26,33,34] 180 levels SMD:-0.69 (-0.20, -1.16); p = .001; 78%
Baseline-end of follow-up 3 [26,33,34] 155 levels SMD: -0.39 (0.05, -0.84); p = .08; 74%
Vertebral height:
% of restitution 3 [25,26,30] 342 levels RR:47% (33%, 61%); 38%
Increase (mm): 2 [33,34] 158 levels
Anterior vertebral body
Basal-postoperative SMD:0.28 (0.06, 0.51); p = .01; 0%
Baseline-end of follow-up SMD: 0.15 (-0.16, 0.45); p = .35; 37%
Midline vertebral body
Basal-postoperative SMD:0.28 (0.003, 0.56); p = .04; 34%
Baseline-end of follow-up SMD:0.15 (-0.17, 0.46); p = .35; 41%
VAS: Visual Analog Scale. SMD: Standardized mean difference ODI: Oswestry Disability Index. WMD: Weighted mean difference. RR: rate ratio. CI: 
Confidence Interval. All based on a random effects meta-analysis.BMC Palliative Care 2009, 8:12 http://www.biomedcentral.com/1472-684X/8/12
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measured vertebral height gained in millimeters. Pooled
analysis of his data showed increases in both anterior and
midline vertebral body after BKP. However, neither of
these increases was statistically maintained at the end of
the follow-up period.
Safety
Cement Leaks
All studies provided safety information. Overall, there
were 41 cement leakages associated with BKP, none of
which was symptomatic. BKP cement leakages occurred at
a mean of approximately 6% across all levels (Figure 2).
Sensitivity analysis showed that inconsistency across stud-
ies (I2: 84%) was related to design, with prospective stud-
ies yielding a higher rate of leakage (11.2%) than
retrospective studies (0.51%, I2: 0%). No relationship was
found with other factors such as specific etiology (multi-
ple myeloma vs. metastasis) or estimated age of the frac-
ture.
In Fourney's study [26], 6 asymptomatic leakages were
observed in the 65 levels treated with vertebroplasty, rep-
resenting 9%, while no leakages were observed in patients
treated with BKP. Kose's comparative study [30] recorded
no cement leaks in patients treated with either BKP or ver-
tebroplasty.
New Vertebral Fractures
After pre-planned radiographic evaluation during follow-
up, four studies reported the development of 21 new ver-
tebral fractures in 172 patients [see Additional file 1].
Although fracture rates varied widely among studies,
pooled analysis showed an overall rate close to 10% (Fig-
ure 3). Sensitivity analysis showed that inconsistency
across studies (I2: 54%) was related to fracture etiology.
The rate of new fractures was higher in patients with mye-
loma (12.4%) than in those with metastasis (7.9%,
I2:0%).
Clinical Complications
Although poorly reported across the studies, a small
number of patients treated with BKP experienced clinical
complications, but no deaths were reported within 30
days of BKP [see Additional file 1]. Two studies reported
complications unrelated to the procedure. In Fourney's
study [26], one patient was readmitted to hospital 15 days
after BKP due to an exacerbation of pre-existing congestive
heart failure, while Vrionis et al. [28] recorded a case of
asystole in a patient with a history of lung cancer with
multiple brain metastases. No evidence of pulmonary
embolism due to cement leakage was seen postoperatively
and the exact cause of asystole was undetermined. That
patient recovered to her preoperative level, but died 1
month after surgery from unrelated causes.
In a comparative study, Kose [30] recorded no post-surgi-
cal neurological or pulmonary complications after any
intervention. Although that article stated that two patients
suffered minor clinical complications (wound infection
and temporary respiratory difficulties while being placed
in position for surgery), the authors did not indicate
which intervention had been performed (i.e., BKP or ver-
tebroplasty).
Discussion
The present study found that there are very few reports on
the efficacy and safety of BKP for treating tumor-associ-
ated spinal fractures. Furthermore, all such reports have a
non-randomized design, and are limited in terms of
number of patients, procedures and reported outcomes.
Nonetheless, a combined analysis of these reports pro-
vided results in broad agreement with earlier reports
examining osteoporotic fractures [15,16,34-37].
The present meta-analysis found that BKP provided
immediate pain relief, and that the relief can continue for
Balloon Kyphoplasty: Meta-analysis of cement leakage Figure 2
Balloon Kyphoplasty: Meta-analysis of cement leak-
age. Random-effects meta-analysis. CI: Confidence interval.
Balloon Kyphoplasty: Meta-analysis on the incidence of new  spinal fractures Figure 3
Balloon Kyphoplasty: Meta-analysis on the incidence 
of new spinal fractures. Random-effects model. CI: Confi-
dence interval.BMC Palliative Care 2009, 8:12 http://www.biomedcentral.com/1472-684X/8/12
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up to 2 years. This pain relief is not only clinically signifi-
cant (i.e., a change of 2.0 - 2.7 points on the VAS, which is
equivalent to a reduction of 30 - 41%) [38], but of great
benefit because most patients have intense and refractory
pain resistant to painkillers and conventional medical
therapy. The mechanism underlying this pain relief
remains to be identified [11].
The current study also found that BKP resulted in
improved functional outcomes. BKP improved functional
capacity as assessed by the Oswestry Disability Index. In
addition, the study that assessed quality of life using the
standard SF-36 questionnaire found improvement in
nearly every domain, including vitality, social function
and mental health. Interestingly, that study found no sig-
nificant improvement in general health perception, which
was not clearly explained but may reflect progression of
the primary malignant disease.
The third major finding of this study was that BKP
appeared to reduce the kyphotic angle and, at least par-
tially, restored the height of the collapsed vertebral body.
However, this evidence was limited due to the diverse
methods used for these assessments. In addition, there
was a progressive postoperative decrease in the amount of
improvement, and the morphologic benefits were not
maintained over the entire follow-up period. Hence, these
findings do not suggest that the technique prevents the
severe physiological and systemic effects of spinal frac-
tures, which is one of its main objectives [13,14].
Regarding safety, it appears that BKP is a safe procedure.
Though BKP was usually performed under general
anesthesia, very few clinical complications were reported,
of which none was serious. No study recorded neurologi-
cal or pulmonary complications. Most studies found that
any clinical complications were not directly related to the
technique but to comorbidities or the progression of the
initial disease. However, given the typical frailty of BKP
patients, the procedure should be carried out in centers
equipped to treat possible neurological or cardiopulmo-
nary complications.
Cement leakages occurred in approximately 6% of all
treated levels. While study design influenced that analysis,
leakages were asymptomatic in all cases. Our results indi-
cate that approximately 10% of patients will develop a
new vertebral collapse within two years after treatment.
The development of new vertebral fractures seems to be
more frequent (nearly double) in patients with multiple
myeloma than in metastatic cases. This is not surprising
given several studies have found myeloma patients are
more vulnerable to fractures [2]. The present figures com-
pare favorably with other published data [15,16,35].
Overall, the data suggest that the incidence of new frac-
tures after a BKP-based intervention is not higher than the
spontaneous incidence of new vertebral fractures (19-
24%) described for untreated patients [8].
Finally, mention should be made to the fact that, at this
time, there is an evident lack of studies comparing BKP
with other interventions, both invasive and non-invasive.
The present findings indicate that BKP and vertebroplasty
provide similar pain relief, but that BKP is associated with
a lower cement leakage rate, as has been observed else-
where [35-37].
The current study has several potential limitations. Publi-
cation bias may exist by limiting our search to peer-
reviewed literature. Nevertheless, we feel that any such
bias would have been minimized by the scope of and sys-
tematic strategy used in the search of the literature, and we
are confident that most research conducted in this field
was identified [17,39]. We did not include unpublished
data from industry given both the difficulties encountered
in obtaining such information and the recognition that
the use of such data may not necessarily reduce the bias in
a meta-analysis [39,40].
The methodological quality of the studies, particularly
their non-randomized design, may constitute another
limitation of this work [20]. To our knowledge, there are
no published reports of randomized clinical trials exam-
ining the use of BKP for malignant spinal fractures. How-
ever, such an absence should not prevent analysis of its
efficacy and safety, and evaluation of new technologies
and procedures, as this would deprive patients, profes-
sionals and health authorities of essential information for
decision-making [41-44]. The present study followed the
guidelines outlined by the Meta-analysis of Observational
Studies in Epidemiology Group [43] in order to identify
and collate relevant data from available studies.
Lastly, we should recognize that the present findings were
based on original studies involving relatively small sam-
ple sizes, making them susceptible to the inherent prob-
lems associated with such a study design [45].
Conclusion
The present study found that there is level III evidence
showing that BKP is a well-tolerated, relatively safe and
effective method for reducing pain and improving func-
tional outcomes in patients with painful neoplastic spinal
fractures. While BKP also provided immediate improve-
ment in vertebral height loss and spinal deformity, these
morphologic changes were not long-term. The limited
data available in this area indicate the need for long-term
high-quality controlled studies to ascertain the clinical
role of BKP for patients with painful neoplastic spinal
fractures. Future studies should also have consistent
reporting of clinically useful outcomes.BMC Palliative Care 2009, 8:12 http://www.biomedcentral.com/1472-684X/8/12
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